Personalized approach to pharmacotherapy of overactive bladder

Abstract

The article provides an overview of modern approaches to pharmacotherapy of overactive bladder. It has been shown that the choice of drug therapy for overactive bladder should be made taking into account the pathophysiological mechanisms of the development of the disease, the characteristics of its clinical course, as well as the potential risks of developing side effects of treatment. A pathogenetic rationale for the choice of treatment tactics for different categories of patients is presented, including those with a hypersensitive bladder, bladder outlet obstruction, neurological and geriatric patients. The pharmacological properties of the β3-adrenergic receptor agonist mirabegron are described, which provide high efficacy and a favorable safety profile in the treatment of patients with overactive bladder. The practical issues of prescribing mirabegron in various clinical situations are considered.

Keywords

overactive bladder / β3-adrenergic receptor / β3-adrenergic agonist / detrusor overactivity / mirabegron

References

[1] Abrams P, Cardozo L, Fall M, et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. DOI: 10.1002/nau.10052

[2] Abrams P., Cardozo L., Fall M., et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society // Neurourol Urodyn. 2002. Vol. 21, No. 2. P. 167–178. DOI: 10.1002/nau.10052

[3] Al-Shukri SK, Kuzmin IV. Quality of life in patients with overactive bladder. Urology reports (St. Petersburg). 2011;1(1):21–26. (In Russ.) DOI: 10.17816/uroved57653

[4] Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря // Урологические ведомости. 2011. Т. 1, № 1. P. 21–26. DOI: 10.17816/uroved57653

[5] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. DOI: 10.1016/j.eururo.2006.09.0193

[6] Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study // Eur Urol. 2006. Vol. 50, No. 6. P. 1306–1314. DOI: 10.1016/j.eururo.2006.09.0193

[7] Kuzmin IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyrya. [dissertation abstract]. Saint Petersburg; 2007. 40 p. (In Russ.)

[8] Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря: автореф. дис. … д-ра мед. наук. Санкт Петербург, 2007. 40 c.

[9] Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urology reports (St. Petersburg). 2015;5(3):30–34. (In Russ.) DOI: 10.17816/uroved5330-34

[10] Кузьмин И.В. Эпидемиологические аспекты гиперактивного мочевого пузыря и ургентного недержания мочи // Урологические ведомости. 2015. Т. 5, № 3. C. 30–34. DOI: 10.17816/uroved5330-34

[11] Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. DOI: 10.1016/j.eururo.2019.02.038

[12] Peyronnet B., Mironska E., Chapple C., et al. A Comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment // Eur Urol. 2019. Vol. 75, No. 6. P. 988–1000. DOI: 10.1016/j.eururo.2019.02.038

[13] Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8):F738–F743. DOI: 10.1152/ajprenal.00333.201521

[14] Thurmond P., Yang J.H., Azadzoi K.M. LUTS in pelvic ischemia: a new concept in voiding dysfunction // Am J Physiol Renal Physiol. 2016. Vol. 310, No. 8. P. F738–F743. DOI: 10.1152/ajprenal.00333.201521

[15] Berdichevsky BA, Berdichevsky VB. Detrusor ischemia. Clinical effects. Urologiia. 2019;(5):132–135. (In Russ.) DOI: 10.18565/urology.2019.5.132-135

[16] Бердичевский Б.А., Бердичевский В.Б. Ишемия детрузора. Клинические эффекты // Урология. 2019. № 5. C. 132–135. DOI: 10.18565/urology.2019.5.132-135

[17] Pinggera G, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008;102(4):470–474. DOI: 10.1111/j.1464-410X.2008.07587.x

[18] Pinggera G., Mitterberger M., Steiner E., et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography // BJU Int. 2008. Vol. 102, No. 4. P. 470–474. DOI: 10.1111/j.1464-410X.2008.07587.x

[19] Al-Shukri SH, Kuzmin IV, Boriskin AG, et al. Correction of microcirculatory disorders in patients with overactive bladder. Nephrology (Saint Petersburg). 2011;15(1):58–64. (In Russ.)

[20] Аль-Шукри С.Х., Кузьмин И.В., Борискин А.Г., и др. Коррекция нарушений микроциркуляции у больных с гиперактивностью мочевого пузыря // Нефрология. 2011. Т. 15, № 1. С. 58–64.

[21] Lee SR, Kim HJ, Kim A, Kim JH. Overactive bladder is not only overactive but also hypersensitive. Urology. 2010;75(5):1053–1059. DOI: 10.1016/j.urology.2009.10.045

[22] Lee S.R., Kim H.J., Kim A., Kim J.H. Overactive bladder is not only overactive but also hypersensitive // Urology. 2010. Vol. 75, No. 5. P. 1053–1059. DOI: 10.1016/j.urology.2009.10.045

[23] Kushida N, Fry CH. On the origin of spontaneous activity in the bladder. BJU Int. 2016;117(6):982–992. DOI: 10.1111/bju.13240

[24] Kushida N., Fry C.H. On the origin of spontaneous activity in the bladder // BJU Int. 2016. Vol. 117, No. 6. P. 982–992. DOI: 10.1111/bju.13240

[25] Chen SL, Ng SC, Huang YH, Chen GD. Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome? J Chin Med Assoc. 2017;80(10):644–650. DOI: 10.1016/j.jcma.2017.03.009

[26] Chen S.L., Ng S.C., Huang Y.H., Chen G.D. Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome? // J Chin Med Assoc. 2017. Vol. 80, No. 10. P. 644–650. DOI: 10.1016/j.jcma.2017.03.009

[27] Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56(5): 810–819. DOI: 10.1016/j.eururo.2009.07.044

[28] Roosen A., Chapple C.R., Dmochowski R.R., et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature // Eur Urol 2009. Vol. 56, No. 5. P. 810–819. DOI: 10.1016/j.eururo.2009.07.044

[29] Kaplan SA, Dmochowski R, Cash BD, et al. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract. 2013;67(3):205–216. DOI: 10.1111/ijcp.12028

[30] Kaplan S.A., Dmochowski R., Cash B.D., et al. Systematic review of the relationship between bladder and bowel function: implications for patient management // Int J Clin Pract. 2013. Vol. 67, No. 3. P. 205–216. DOI: 10.1111/ijcp.12028

[31] Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69:199–217. DOI: 10.1111/ijcp.12518

[32] Bunn F., Kirby M., Pinkney E., et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies // Int J Clin Pract. 2015. Vol. 69. P. 199–217. DOI: 10.1111/ijcp.12518

[33] Vrijens D, Drossaerts J, van Koeveringe G, et al. Affective symptoms and the overactive bladder — a systematic review. J Psychosom Res. 2015;78:95–108. DOI: 10.1016/j.jpsychores.2014.11.019

[34] Vrijens D., Drossaerts J., van Koeveringe G., et al. Affective symptoms and the overactive bladder — a systematic review // J Psychosom Res. 2015. Vol. 78. P. 95–108. DOI: 10.1016/j.jpsychores.2014.11.019

[35] Javan Balegh Marand A, Baars C, Heesakkers J, et al. Differences in the urinary microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements. Life (Basel). 2023;13(5):1199. DOI: 10.3390/life13051199

[36] Javan Balegh Marand A., Baars C., Heesakkers J., et al. Differences in the urinary microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements // Life (Basel). 2023. Vol. 13, No. 5. P. 1199. DOI: 10.3390/life13051199

[37] Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21–27. DOI: 10.1111/j.1442-2042.2012.03196.x19

[38] Hood B., Andersson K.E. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder // Int J Urol. 2013. Vol. 20, No. 1. P. 21–27. DOI: 10.1111/j.1442-2042.2012.03196.x19

[39] Nederzhanie mochi. Klinicheskie rekomendatsii Minzdrava RF. 2020 [cited: 2023 Sept 02]. Available from: http://cr.rosminzdrav.ru/recomend/8_1

[40] Недержание мочи. Клинические рекомендации Минздрава РФ. 2020. Режим доступа: http://cr.rosminzdrav.ru/recomend/8_1 Дата обращения: 02.09.2023.

[41] Harding CK, Lapitan MC, Arlandis S, et al. European Association of Urology. Management of non-neurogenic female lower urinary tract symptoms (LUTS). EAU Guideline. 2023 [cited: 2023 Sept 02] Available from: https://uroweb.org/guidelines/non-neurogenic-female-luts

[42] Harding CK, Lapitan MC, Arlandis S, et al; European Association of Urology. Management of non-neurogenic female lower urinary tract symptoms (LUTS). EAU Guideline. 2023. Режим доступа: https://uroweb.org/guidelines/non-neurogenic-female-luts. Дата обращения: 02.09.2023.

[43] Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12(12): CD003193. DOI: 10.1002/14651858.CD003193.pub422

[44] Rai B.P., Cody J.D., Alhasso A., Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults // Cochrane Database Syst Rev. 2012. Vol. 12, No. 12. P. CD003193. DOI: 10.1002/14651858.CD003193.pub422

[45] Sartori LGF, Nunes BM, Farah D, et al. Mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis. Rev Bras Ginecol Obstet. 2023;45(6):337–346. DOI: 10.1055/s-0043-1770093

[46] Sartori L.G.F., Nunes B.M., Farah D., et al. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis // Rev Bras Ginecol Obstet. 2023. Vol. 45, No. 6. P. 337–346. DOI: 10.1055/s-0043-1770093

[47] Alyaev YuG, Gadzhieva ZK. M-kholinoblokatory v lechenii giperaktivnogo mochevogo puzyrya. Effektivnaya Farmakoterapiya. 2010;(29):28–35.

[48] Аляев Ю.Г., Гаджиева З.К. М-холиноблокаторы в лечении гиперактивного мочевого пузыря // Эффективная фармакотерапия. 2010. № 29. С. 28–35.

[49] Kasjan GR. Mirabegron — a new drug for treatment of overactive bladder. Urologiia. 2015;(4):121–124. (In Russ.)

[50] Касян Г.Р. Мирабегрон — новый препарат для лечения гиперактивного мочевого пузыря // Урология. 2015. № 4. С. 121–124.

[51] Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;(1):120–125. (In Russ.) DOI: 10.18565/urology.2021.1.120–125

[52] Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? // Урология. 2021. № 1. С. 120–125.

[53] Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5): 273–279 (In Russ.) DOI: 10.32364/2587-6821-2021-5-5-273-279

[54] Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты // РМЖ. Медицинское обозрение. 2021. Т. 5, № 5. С. 273–279.

[55] Ehlert FJ, Ahn S, Pak KJ, et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder. J Pharmacol Exp Ther. 2007;322(2):631–637. DOI: 10.1124/jpet.107.121756

[56] Ehlert F.J., Ahn S., Pak K.J., et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder // J Pharmacol Exp Ther. 2007. Vol. 322, No. 2. P. 631–637. DOI: 10.1124/jpet.107.121756

[57] Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80–S87. DOI: 10.1038/sj.bjp.0706560

[58] Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics // Br J Pharmacol. 2006. Vol. 147, Suppl 2. P. S80–S87. DOI: 10.1038/sj.bjp.0706560

[59] Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458. DOI: 10.1007/s00192-013-2042-x

[60] Chapple C.R., Dvorak V., Radziszewski P., et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder // Int Urogynecol J. 2013. Vol. 24, No. 9. P. 1447–1458. DOI: 10.1007/s00192-013-2042-x

[61] Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: Results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–985. DOI: 10.1111/ijcp.12433

[62] Nitti V.W., Chapple C.R., Walters C., et al. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: Results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial // Int J Clin Pract 2014. Vol. 68, No. 8. P. 972–985. DOI: 10.1111/ijcp.12433

[63] Kanai A, Wyndaele J, Andersson K, et al. Researching bladder afferents-determining the effects of β3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol. Urodyn. 2011;30(5):684–691. DOI: 10.1002/nau.21102

[64] Kanai A., Wyndaele J., Andersson K., et al. Researching bladder afferents determining the effects of β3-adrenergic receptor agonists and botulinumtoxin type-A // Neurourol Urodyn. 2011. Vol. 30, No. 5. P. 684–691. DOI: 10.1002/nau.21102

[65] Krivoborodov GG, Tur EI, Shirin DA. Hyperactive bladder the concept of disease and paradigms in the treatment. Medical Council. 2021;(4):121–126. (In Russ.) DOI: 10.21518/2079-701X-2021-4-121-126

[66] Кривобородов Г.Г., Тур Е.И., Ширин Д.А. Гиперактивный мочевой пузырь: концепция заболевания и подходы к лечению // Медицинский совет. 2021. Т. 4. С. 121–126. DOI: 10.21518/2079-701X-2021-4-121-126

[67] Romikh VV, Zakharchenko AV, Kukushkina LYu, et al. Current concepts of the overactive bladder in women. Strategy for choosing drug therapy. Obstetrics and Gynecology. 2021;(8):183–191. (In Russ.) DOI: 10.18565/aig.2021.8.183-191

[68] Ромих В.В., Захарченко А.В., Кукушкина Л.Ю., и др. Современные представления о гиперактивном мочевом пузыре у женщин. Стратегия выбора лекарственной терапии // Акушерство и гинекология. 2021. № 8. С. 183–191. DOI: 10.18565/aig.2021.8.183-191

[69] Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology Reports (St. Petersburg). 2020;10(2):163–171. (In Russ.) DOI: 10.17816/uroved102163-171

[70] Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты // Урологические ведомости. 2020. Т. 10, № 2. P. 163–171. DOI: 10.17816/uroved102163-171

[71] Resolution of the expert board on urodynamics and neurourology sections of neurourology of the Russian society of urology (ROU) OCTOBER8, 2022 (SOCHI) Urology. 2022;(6):134–136. DOI: 10.18565/urology.2022.6.134-136

[72] Резолюция Экспертного совета по уродинамике и нейроурологии секции нейроурологии Российского общества урологов. (РОУ) 8 октября 2022 г. (Сочи) // Урология. 2022. № 6. С. 134–136. DOI: 10.18565/urology.2022.6.134-136

[73] Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558–563. DOI: 10.1097/JU.000000000000030921

[74] Lightner D.J., Gomelsky A., Souter L., Vasavada S.P. Diagnosis and Treatment of Overactive Bladder. (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019 // J Urol. 2019. Vol. 202, No. 3. P. 558–563. DOI: 10.1097/JU.000000000000030921

[75] Liao CH, Kuo HC. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine (Baltimore). 2016;95(45):e4962. DOI: 10.1097/MD.0000000000004962

[76] Liao C.H., Kuo H.C. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment // Medicine (Baltimore). 2016. Vol. 95, No. 45. P. e4962. DOI: 10.1097/MD.0000000000004962

[77] Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827–838. DOI: 10.1007/s00345-016-1908-1

[78] Abrams P., Kelleher C., Staskin D., et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY) // World J Urol. 2017. Vol. 35, No. 5. P. 827–838. DOI: 10.1007/s00345-016-1908-1

[79] Apostolidis A, Averbeck MA, Sahai A, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS2015). Neurourol Urodyn. 2017;36(4):882–893. DOI: 10.1002/nau.23170

[80] Apostolidis A., Averbeck M.A., Sahai A., et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS2015) // Neurourol Urodyn. 2017. Vol. 36, No. 4. P. 882–893. DOI: 10.1002/nau.23170

[81] Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology Reports (St. Petersburg). 2022;12(1):71–84 (In Russ.) DOI: 10.17816/uroved104335

[82] Кузьмин И.В., Слесаревская М.Н., Амдий Р.Э., и др. Длительная ботулинотерапия гиперактивного мочевого пузыря: мифы и реальность // Урологические ведомости. 2022. Т. 12, № 1. P. 71–84.

[83] Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: A randomised, multicentre trial. Int J Clin Pract. 2011;65(9):997–1004. DOI: 10.1111/j.1742-1241.2011.02728.x

[84] Lee Y.S., Choo M.S., Lee J.Y., et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: A randomised, multicentre trial // Int J Clin Pract. 2011. Vol. 65, No. 9. P. 997–1004. DOI: 10.1111/j.1742-1241.2011.02728.x

[85] Shim EJ, Yoo EH, Kim YM, Kim D. Factors affecting medication discontinuation in patients with overactive bladder symptoms. Obstet Gynecol Sci. 2015;58(6):507–513. DOI: 10.5468/ogs.2015.58.6.507

[86] Shim E.J., Yoo E.H., Kim Y.M., Kim D. Factors affecting medication discontinuation in patients with overactive bladder symptoms // Obstet Gynecol Sci. 2015. Vol. 58, No. 6. P. 507–513. DOI: 10.5468/ogs.2015.58.6.507

[87] Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–350. DOI: 10.5489/cuaj.3098

[88] Wagg A., Franks B., Ramos B., Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada // Can Urol Assoc J. 2015. Vol. 9, No. 9–10. P. 343–350. DOI: 10.5489/cuaj.3098

[89] Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–399. DOI: 10.1016/j.eururo.2017.01.037

[90] Chapple C.R., Nazir J., Hakimi Z., et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice // Eur Urol. 2017. Vol. 72, No. 3. P. 389–399. DOI: 10.1016/j.eururo.2017.01.037

[91] Wang CC, Jiang YH, Ong HL, Kuo HC. Higher urge severity scale predicts the recurrence of overactive bladder symptoms after discontinuing mirabegron in patients with overactive bladder. ICS Abstract. 2017;(479).

[92] Wang C.C., Jiang Y.H., Ong H.L., Kuo H.C. Higher urge severity scale predicts the recurrence of overactive bladder symptoms after discontinuing mirabegron in patients with overactive bladder // ICS Abstract. 2017. No. 479.

[93] Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6(4):179–188. DOI: 10.1159/000343536

[94] Patra P.B., Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract // Curr Urol. 2013. Vol. 6, No. 4. P. 179–188. DOI: 10.1159/000343536

[95] Spradling K, Khoyilar C, Abedi G, et al. Redefining the autonomic nerve distribution of the bladder using 3-dimensional image reconstruction. J Urol. 2015;194(6):1661–1667. DOI: 10.1016/j.juro.2015.05.077

[96] Spradling K., Khoyilar C., Abedi G., et al. Redefining the autonomic nerve distribution of the bladder using 3-dimensional image reconstruction // J Urol. 2015. Vol. 194, No. 6. P. 1661–1667. DOI: 10.1016/j.juro.2015.05.077

[97] Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptors subtypes in male and female normal human urinary bladder. Urology. 2002;60(4):719–725. DOI: 10.1016/s0090-4295(02)01819-8

[98] Sigala S., Mirabella G., Peroni A., et al. Differential gene expression of cholinergic muscarinic receptors subtypes in male and female normal human urinary bladder // Urology. 2002. Vol. 60, No. 4. P. 719–725. DOI: 10.1016/s0090-4295(02)01819-8

[99] Sugaya K, Nishijima S, Kadekawa K, et al. Relation between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactibe bladder. Biomed Res. 2009;30(5):287–294. DOI: 10.2220/biomedres.30.287

[100] Sugaya K., Nishijima S., Kadekawa K., et al. Relation between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactibe bladder // Biomed Res. 2009. Vol. 30, No. 5. P. 287–294. DOI: 10.2220/biomedres.30.287

[101] Morita T, Masuda H, Tosaka A, et al. Sex differences in function and distribution of beta-adrenoceptors in rabbit urinary bladder. J Urol. 1998;159:555–558. DOI: 10.1016/s0022-5347(01)63982-x

[102] Morita T., Masuda H., Tosaka A., et al. Sex differences in function and distribution of beta-adrenoceptors in rabbit urinary bladder // J Urol. 1998. Vol. 159. P. 555–558. DOI: 10.1016/s0022-5347(01)63982-x

[103] Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087. DOI: 10.1016/j.urology.2010.08.039

[104] Coyne K.S., Sexton C.C., Vats V., et al. National community prevalence of overactive bladder in the United States stratified by sex and age // Urology. 2011. Vol. 77, No. 5. P. 1081–1087. DOI: 10.1016/j.urology.2010.08.039

[105] Sekido N, Hinotsu S, Kawai K, et al. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? Int J Urol. 2006;13(10):1276–1279. DOI: 10.1111/j.1442-2042.2006.01558.x

[106] Sekido N., Hinotsu S., Kawai K., et al. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? // Int J Urol. 2006. Vol. 13, No. 10. P. 1276–1279. DOI: 10.1111/j.14422042.2006.01558.x

[107] Slesarevskaya MN, Ignashov YA, Kuzmin IV, Al-Shukri SK. Persistent dysuria in women: etiological diagnostics and treatment. Urology reports (St. Petersburg). 2021;11(3):195–204 (In Russ.) DOI: 10.17816/uroved81948

[108] Слесаревская М.Н., Игнашов Ю.А., Кузьмин И.В., Аль-Шукри С.Х. Стойкая дизурия у женщин: этиологическая диагностика и лечение // Урологические ведомости. 2021. Т. 11, № 3. C. 195–204. DOI: 10.17816/uroved81948

[109] Al-Ghazo MA, Ghalayini IF, Al-Azab R, et al. Urodynamic detrusor overactivity in patients with overactive bladder symptoms. Int Neurourol J. 2011;15(1):48–54. DOI: 10.5213/inj.2011.15.1.48

[110] Al-Ghazo M.A., Ghalayini I.F., Al-Azab R., et al. Urodynamic detrusor overactivity in patients with overactive bladder symptoms // Int Neurourol J. 2011. Vol. 15, No. 1. P. 48–54. DOI: 10.5213/inj.2011.15.1.48

[111] Blanc F, Pichot V, Roche F, et al. Activity of the autonomous nervous system measured based on the variability of heart rate in female urinary incontinence. Prog Urol. 2001;11(3):492–497. (In French.)

[112] Blanc F., Pichot V., Roche F., et al. Activité du système nerveux autonome mesurée par la variabilité de la fréquence cardiaque dans l’incontinence urinaire feminine // Prog Urol. 2001. Vol. 11, No. 3. P. 492–497.

[113] Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology. 2005;65: 1109–1112. Discussion 1113. DOI: 10.1016/j.urology.2005.01.029

[114] Choi J.B., Kim Y.B., Kim B.T., Kim Y.S. Analysis of heart rate variability in female patients with overactive bladder // Urology. 2005. Vol. 65. P. 1109–1112. Discussion 1113. DOI: 10.1016/j.urology.2005.01.029

[115] Hubeaux K, Deffieux X, Ismael SS, et al. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol. 2007;178(6):2483–2487. DOI: 10.1016/j.juro.2007.08.036

[116] Hubeaux K., Deffieux X., Ismael S.S., et al. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence // J Urol. 2007. Vol. 178, No. 6. P. 2483–2487. DOI: 10.1016/j.juro.2007.08.036

[117] Hubeaux K, Deffieux X, Raibaut P, et al. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. Neurourol Urodyn. 2011;30:1467–1472. DOI: 10.1002/nau.21154

[118] Hubeaux K., Deffieux X., Raibaut P., et al. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome // Neurourol Urodyn. 2011. Vol. 30. P. 1467–1472. DOI: 10.1002/nau.21154

[119] Chen YC, Chen HW, Huang TC, et al. Skin sympathetic nerve activity as a potential biomarker for overactive bladder. World J Urol. 2023;41(5):1373–1379. DOI: 10.1007/s00345-023-04376-16

[120] Chen Y.C., Chen H.W., Huang T.C., et al. Skin sympathetic nerve activity as a potential biomarker for overactive bladder // World J Urol. 2023. Vol. 41, No. 5. P. 1373–1379. DOI: 10.1007/s00345-023-04376-16

[121] Ates E, Ipekci T, Akin Y, et al. Impact of sympathetic dysfunction in the etiology of overactive bladder in women: A preliminary study. Neurourol Urodyn. 2016;35(1):26–28. DOI: 10.1002/nau.22652

[122] Ates E., Ipekci T., Akin Y., et al. Impact of sympathetic dysfunction in the etiology of overactive bladder in women: A preliminary study // Neurourol Urodyn. 2016. Vol. 35, No. 1. P. 26–28. DOI: 10.1002/nau.22652

[123] Hsiao SM, Tu FC, Su TC, et al. Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial. Sci Rep. 2022;12(1):14219. DOI: 10.1038/s41598-022-18391-6

[124] Hsiao S.M., Tu F.C., Su T.C., et al. Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial // Sci Rep. 2022. Vol. 12, No. 1. P. 14219. DOI: 10.1038/s41598-022-18391-6

[125] Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36(8):2123–2131. DOI: 10.1002/nau.23256

[126] Lua L.L., Pathak P., Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents // Neurourol Urodyn. 2017. Vol. 36, No. 8. P. 2123–2131. DOI: 10.1002/nau.23256

[127] Krhut J, Martan A, Zachoval R, et al. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur J Obstet Gynecol Reprod Biol. 2016;196:64–68. DOI: 10.1016/j.ejogrb.2015.11.018

[128] Krhut J., Martan A., Zachoval R., et al. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females // Eur J Obstet Gynecol Reprod Biol. 2016. Vol. 196. P. 64–68. DOI: 10.1016/j.ejogrb.2015.11.018

[129] Kallner HK, Elmér C, Andersson KE, Altman D. Hormonal influence on the effect of mirabegron treatment for overactive bladder. Menopause. 2016;23(12):1303–1306. DOI: 10.1097/GME.0000000000000708

[130] Kallner H.K., Elmér C., Andersson K.E., Altman D. Hormonal influence on the effect of mirabegron treatment for overactive bladder // Menopause 2016. Vol. 23, No. 12. P. 1303–1306. DOI: 10.1097/GME.0000000000000708

[131] Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2): 419–426. DOI: 10.1016/j.eururo.2008.02.017

[132] Oelke M., Baard J., Wijkstra H., et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia // Eur Urol. 2008. Vol. 54, No. 2. P. 419–426. DOI: 10.1016/j.eururo.2008.02.017

[133] Kurizaki Y, Ishizuka O, Imamura T, et al. Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011;45(1):15–19. DOI: 10.3109/00365599.2010.515611

[134] Kurizaki Y., Ishizuka O., Imamura T., et al. Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms // Scand J Urol Nephrol. 2011. Vol. 45, No. 1. P. 15–19. DOI: 10.3109/00365599.2010.515611

[135] Kurizaki Y, Ishizuka O, Imamura T, et al. Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013;32(1):88–91. DOI: 10.1002/nau.22278

[136] Kurizaki Y., Ishizuka O., Imamura T., et al. Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms // Neurourol Urodyn. 2013. Vol. 32, No. 1. P. 88–91. DOI: 10.1002/nau.22278

[137] Kim JC, Yoo JS, Park EY, et al. Muscarinic and purinergic receptor expression in urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int. 2007;101(3):371–375. DOI: 10.1111/j.1464-410X.2007.07251.x

[138] Kim J.C., Yoo J.S., Park E.Y., et al. Muscarinic and purinergic receptor expression in urothelium of rats with detrusor overactivity induced by bladder outlet obstruction // BJU Int. 2007. Vol. 101, No. 3. P. 371–375. DOI: 10.1111/j.1464-410X.2007.07251.x

[139] Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. Urology. 2013;81(5):1030–1033. DOI: 10.1016/j.urology.2013.01.018

[140] Liao C.H., Kuo Y.C., Kuo H.C. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms // Urology. 2013. Vol. 81, No. 5. P. 1030–1033. DOI: 10.1016/j.urology.2013.01.018

[141] Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327. DOI: 10.1016/j.juro.2013.05.062

[142] Nitti V.W., Rosenberg S., Mitcheson D.H., et al. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction // J Urol. 2013. Vol. 190, No. 4. P. 1320–1327. DOI: 10.1016/j.juro.2013.05.062

[143] Neirogennaya disfunktsiya nizhnikh mochevyvodyashchikh putei. Klinicheskie rekomendatsii Minzdrava RF. 2020 [cited 2023 Sept 12]. Available from: https://cr.minzdrav.gov.ru/schema/588_2.

[144] Нейрогенная дисфункция нижних мочевыводящих путей. Клинические рекомендации Минздрава РФ. 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/588_2. Дата обращения: 12.09.2023

[145] Haab F. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn. 2014;33(Suppl 3): S2–S5. DOI: 10.1002/nau.2263

[146] Haab F. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder // Neurourol Urodyn. 2014. Vol. 33. Suppl 3. P. S2–S5. DOI: 10.1002/nau.2263

[147] Kuzmin IV. Dysfunctions of the lower urinary tract in patients with multiple sclerosis. Pathogenesis, symptomatics, diagnosis. Urology reports (St. Petersburg). 2023;13(2):145–156. (In Russ.) DOI: 10.17816/uroved529654

[148] Кузьмин И.В. Дисфункции нижних мочевых путей у больных рассеянным склерозом. Патогенез, симптоматика, диагностика // Урологические ведомости. 2023. Т. 13, № 2. C. 145–156. DOI: 10.17816/uroved529654

[149] Mehnert U, Chartier-Kastler E, de Wachter S, et al. The management of urine storage dysfunction in the neurological patient. SN Compr Clin Med. 2019;(1):160–182. DOI: 10.1007/s42399-018-0005-8

[150] Mehnert U., Chartier-Kastler E., de Wachter S, et al. The management of urine storage dysfunction in the neurological patient // SN Compr Clin Med. 2019. No. 1. P. 160–182. DOI: 10.1007/s42399-018-0005-8

[151] Tibaek S, Gard G, Klarskov P, et al. Prevalence of lower urinary tract symptoms (LUTS) in stroke patients: a cross-sectional, clinical survey. Neurourol Urodyn. 2008;27(8):763–771. DOI: 10.1002/nau.20605

[152] Tibaek S., Gard G., Klarskov P., et al. Prevalence of lower urinary tract symptoms (LUTS) in stroke patients: a cross-sectional, clinical survey // Neurourol Urodyn. 2008. Vol. 27, No. 8. P. 763–771. DOI: 10.1002/nau.20605

[153] Quarto G, Autorino R, Gallo A, et al. Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(2):189–194. DOI: 10.1007/s00192-006-0131-9

[154] Quarto G., Autorino R., Gallo A., et al. Quality of life in women with multiple sclerosis and overactive bladder syndrome // Int Urogynecol J Pelvic Floor Dysfunct. 2007. Vol. 18, No. 2. P. 189–194. DOI: 10.1007/s00192-006-0131-9

[155] Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432–441. DOI: 10.1038/sc.2013.19

[156] Madersbacher H., Mürtz G., Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics // Spinal Cord. 2013. Vol. 51, No. 6. P. 432–441. DOI: 10.1038/sc.2013.19

[157] Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2): 414–421. DOI: 10.1002/nau.22945

[158] Amarenco G., Sutory M., Zachoval R., et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study // Neurourol Urodyn. 2017. Vol. 36, No. 2. P. 414–421. DOI: 10.1002/nau.22945

[159] Blok B, Castro-Diaz D, Del Popolo G, et al; Guideline of European Urological Association. Neuro-Urology. 2023 [cited: 2023 Sept 02]. Available from: https://uroweb.org/guideline/neuro-urology.

[160] Blok B., Castro-Diaz D., Del Popolo G., et al; Guideline of European Urological Association. Neuro-Urology. 2023. Режим доступа: https://uroweb.org/guideline/neuro-urology. Дата обращения: 02.09.2023.

[161] Krivoborodov GG, Kuzmin IV, Romikh VV. Аbobotulinum toxin A (Dysport®) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;2:122–129. (In Russ.) DOI: 10.18565/urology.2023.2.122-12

[162] Кривобородов Г.Г., Кузьмин И.В., Ромих В.В. Абоботулотоксин А (Диспорт®) в лечении нейрогенной гиперактивности детрузора // Урология. 2023. Т. 2. С. 122–129.

[163] Pontari MA, Braverman AS, Ruggieri MR Jr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol. 2004;286(5):R874–R880. DOI: 10.1152/ajpregu.00391.2003

[164] Pontari M.A., Braverman A.S., Ruggieri M.R. Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction // Am J Physiol Regul Integr Comp Physiol. 2004. Vol. 286, No. 5. P. R874–R880. DOI: 10.1152/ajpregu.00391.2003

[165] Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–174. DOI: 10.1111/j.1755-5949.2011.00248.x

[166] Chancellor M., Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects // CNS Neurosci Ther. 2012. Vol. 18, No. 2. P. 167–174. DOI: 10.1111/j.1755-5949.2011.00248.x

[167] Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11–12):21–34. (In Russ.) DOI: 10.26347/1607-2499202111-12021-034

[168] Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты // Клиническая геронтология. 2021. Т. 27, № 11–12. С. 21–34.

[169] Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. DOI: 10.1038/sc.2015.195

[170] Wollner J., Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury // Spinal Cord. 2016. Vol. 54, No. 1. P. 78–82. DOI: 10.1038/sc.2015.195

[171] Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336. DOI: 10.1007/s00345-002-0301-4

[172] Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States // World J Urol. 2003. Vol. 20, No. 6. P. 327–336. DOI: 10.1007/s00345-002-0301-4

[173] Pranovich AA, Satardinova EE, Prashayeuv KI. Biomarkers of pathological aging of urothelia. Clinical Gerontology. 2018;(3–4):8–12. (In Russ.) DOI: 10.26347/1607-2499201803-04008-012

[174] Пранович А.А., Сатардинова Э.Е., Прощаев К.И. Биомаркеры патологического старения уротелия // Клиническая геронтология. 2018. № 3–4. С. 8–12. DOI: 10.26347/1607-2499201803-04008-012

[175] Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St. Petersburg). 2021;11(3):241–256. (In Russ.) DOI: 10.17816/uroved70710

[176] Шорманов И.С., Соловьев А.С., Тюзиков И.А., Куликов С.В. Анатомо-физиологические и патофизиологические особенности нижних мочевых путей в гендерном и возрастном аспектах // Урологические ведомости. 2021. Т. 11, № 3. C. 241–256. DOI: 10.17816/uroved70710

[177] Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology Reports (St. Petersburg). 2022;12(2):127–135 (In Russ.) DOI: 10.17816/uroved108475

[178] Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы // Урологические ведомости. 2022. Т. 12, № 2. P. 127–135. DOI: 10.17816/uroved108475

[179] Kay GG, Abou-Donia MB, Messer WS Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–2201. DOI: 10.1111/j.1532-5415.2005.00537.x

[180] Kay G.G., Abou-Donia M.B., Messer W.S. Jr., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients // J Am Geriatr Soc. 2005. Vol. 53, No. 12. P. 2195–2201. DOI: 10.1111/j.1532-5415.2005.00537.x

[181] Nakagomi H, Mitsui T, Shimura H, et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022;22(1):40. DOI: 10.1186/s12894-022-00989-7

[182] Nakagomi H., Mitsui T., Shimura H., et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study) // BMC Urol. 2022. Vol. 22, No. 1. P. 40. DOI: 10.1186/s12894-022-00989-7

[183] Özcan C, Sancı A, Beyatlı M, et al. The efficiency and safety of mirabegron monotherapy for the treatment of urge incontinence in women aged >80 Years. Cureus. 2023;15(1):e33685. DOI: 10.7759/cureus.33685

[184] Özcan C., Sancı A., Beyatlı M., et al. The efficiency and safety of mirabegron monotherapy for the treatment of urge incontinence in women aged >80 years // Cureus. 2023. Vol. 15, No. 1. P. e33685. DOI: 10.7759/cureus.33685

RIGHTS & PERMISSIONS

Eco-Vector